The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure
Abstract
Background: The beneficial effects of the β-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven. However, its efficacy in patients in whom β-blockers have traditionally been contraindicated or caution has been advised has not been clearly determined. Therefore, analyses in high-risk subgroups of patients taking part in CIBIS II have been performed to investigate the effect of bisoprolol in elderly patients, in patients with type 2 diabetes, with renal failure, NYHA functional class IV or concomitantly treated with digitalis, aldosterone antagonists or amiodarone. Methods: High-risk subgroups of patients with chronic heart failure taking part in the CIBIS II study were retrospectively analysed with respect to mortality, hospitalisation, combined endpoint of cardiovascular mortality or hospitalisation for cardiovascular reasons and treatment withdrawal as well as cause of death and hospitalisation. Analysis is based on intention-to-treat. Results: It was demonstrated that in spite of the expected increase in the overall risk of death and hospitalisation, patients who are diabetic, have renal impairment, NYHA class IV symptoms, are elderly, are taking either digitalis, amiodarone or aldosterone antagonists as co-medication benefit equally from β-blockade with bisoprolol as patients without these complications or drugs. Benefit was shown for the primary endpoint all cause mortality, as well as for the secondary endpoints. Conclusions: Contrary to the hitherto prevailing doctrine of not using beta-blockers in high risk patient groups with chronic heart failure, retrospective analyses of the CIBIS II study justify the use of this drug class in patients regardless of age, NYHA functional class, the presence of diabetes, renal impairment or concomitant treatment with digitalis, amiodarone or aldosterone antagonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ARBs have similar treatment effects in patients with HFrEF with or without diabetes.513-515”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [513]
In the citing paper
“Subgroup analyses of large HF trials show that beta-blockers reduce mortality and hospitalization and improve symptoms in moderate to severe HF, irrespectively of T2DM.37,152,153”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [152]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart Failure
Hillege, H. L., Girbes, A. R. J., de Kam, P. J., Boomsma, F., de Zeeuw, D., Charlesworth, A., Hampton, J. R., & van Veldhuisen, D. J. (2000) · Circulation · doi:10.1161/01.cir.102.2.203 · Cited by 1,045
β-Adrenergic Receptor Blockade in Chronic Heart Failure
Bristow, M. R. (2000) · Circulation · doi:10.1161/01.cir.101.5.558 · Cited by 1,028
Gottlieb, S. S., McCarter, R. J., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 982
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Research works printed but not linked: 3
- Eichorn, 1999, Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure, Am J Cardiol, 83, 1A
- Packer, 1999, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus Recommendations for the Management of Chronic Heart Failure, II. Management of heart failure: approaches to the prevention of heart failure, Am J Cardiol, 83, 9A
- Gottlieb, 1998, Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction, New Engl J Med, 339, 489, 10.1056/NEJM199808203390801 · DOI · Paper page
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., Kurella Tamura, M., & Feldman, H. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.416 · Cited by 1,779
Flather, M. D., Shibata, M. C., Coats, A. J. S., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., Cohen-Solal, A., Dumitrascu, D., Ferrari, R., Lechat, P., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi115 · Cited by 1,655
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 922
Metadata
- Authors
- Erland, E., Philippe, L., Patricia, V., & Hermann, W.
- Affiliations
- University of Cologne , Joseph-Stelzmann-Str. 9, 50924, Cologne ,
- Hôpital Pitié Salpétrière , 47, Boulevard de l'Hôpital, F-75651, Paris Cedex 13 ,
- Merck KGaA , Frankfurter Str. 250, D-64271, Darmstradt ,
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-08-01
- Volume
- 3
- Issue
- 4
- Pages
- 469-479
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W1987016701
- Cited by
- 190
- References
- 26
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 6 · 2013: 3 · 2012: 9
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- bisoprolol, chronic heart failure, beta-blockers, high-risk patient subgroups, type 2 diabetes, renal dysfunction, elderly patients, NYHA functional class IV, digitalis, amiodarone, mineralocorticoid receptor antagonists, all-cause mortality, hospitalization, treatment withdrawal
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Cause of Death, Chronic Disease, Diabetes Mellitus, Type 2, Female, Germany, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Probability, Reference Values, Retrospective Studies, Risk Factors, Severity of Illness Index, Confidence Intervals, Survival Analysis, Treatment Outcome, Bisoprolol, Age Distribution, Sex Distribution, Risk Assessment, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure. https://app.cochat.ai/papers/10.1016/s1388-9842(01)00174-x
- The paper
- Erland, E., Philippe, L., Patricia, V., & Hermann, W. (2001). Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure. European Journal of Heart Failure. https://doi.org/10.1016/s1388-9842(01)00174-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.